Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer
MTAP loss is among the most common potentially targetable driver mutations in NSCLC. Early phase clinical trials are ongoing. Although susceptible to various biases, retrospective studies may serve as a historical control to interpret single arm studies. Combination therapies and novel biomarkers may also improve objective response rates.
Authors
- Edward B. Garon (ORCID: https://orcid.org/0000-0001-7077-8801)
- Daniel Li (ORCID: https://orcid.org/0000-0003-4293-4509)
Institutions
- University of California, Los Angeles (US)
- University of Santa Monica (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-09-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-2458
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00